| Literature DB >> 35493477 |
Sepide Behrouz1, Saeideh Saadat2,3, Arghavan Memarzia4, Hadi Sarir1, Gert Folkerts5, Mohammad Hossein Boskabady3,4.
Abstract
Camel milk (CM) has been found to have several health benefits, including antiviral, antibacterial, anti-tumor, anti-fungal, antioxidant, hypoglycaemic and anti-cancer activities. In addition, CM can counter signs of aging and may be a useful naturopathic treatment for autoimmune diseases. The composition of CM varies with geographic origin, feeding conditions, seasonal and physiological changes, genetics and camel health status. In the present review, we collate the diverse scientific literature studying antioxidant, anti-inflammatory and immunomodulatory effects of CM and its bioactive compounds. The databases Scopus, PubMed, and Web of Science were searched until the end of September 2021 using the keywords: camel milk, antioxidant, anti-inflammatory, immunomodulatory. The anti-inflammatory mechanism of CM in various inflammatory disorders was consistently reported to be through modulating inflammatory cells and mediators. The common anti-inflammatory bioactive components of CM seem to be lactoferrin. The antioxidant effects of α-lactalbumin, β-caseins and vitamin C of CM work by reducing or inhibiting the production of reactive oxygen species (ROS), hydroxyl radicals, nitric oxide (NO), superoxide anions and peroxyl radicals, likely alleviating oxidative stress. Higher levels of protective proteins such as lysozyme, IgG and secretory IgA compared to cow's milk, and insulin-like protein activity of CM on ß cells appear to be responsible for the immunomodulatory properties of CM. The evidence indicates that CM and its bioactive components has the potential to be a therapeutic value for diseases that are caused by inflammation, oxidative stress and/or immune-dysregulation.Entities:
Keywords: anti-inflammatory; antioxidant; camel milk; immunomodulatory; treatment
Mesh:
Substances:
Year: 2022 PMID: 35493477 PMCID: PMC9039309 DOI: 10.3389/fimmu.2022.855342
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1Flowchart of searching and selecting articles for the current review.
Compositions of camel milk (%) (14).
| Species | Fat | Protein | Lactose | Ash | Total Solids |
|---|---|---|---|---|---|
| Camel | 4.9 | 3.7 | 5.1 | 0.7 | 14.4 |
| Cow | 4.5 | 3.8 | 4.9 | 0.72 | 13.9 |
| Buffalo | 7.6 | 3.8 | 4.9 | 0.78 | 17 |
| Ewe | 5.3 | 5.5 | 4.6 | 0.9 | 16.3 |
| Goat | 3.5 | 3.1 | 4.6 | 0.79 | 12 |
| Mare | 1.6 | 2.7 | 6.1 | 0.51 | 11 |
| Ass | 1.2 | 1.7 | 6.9 | 0.45 | 10.2 |
| Reindeer | 18 | 11 | 1.5 | – | 33 |
| Elephant | 15.1 | 4.9 | 3.4 | 0.76 | 26.9 |
| Women breast milk | 4.5 | 1.1 | 6.8 | 0.2 | 12.6 |
Anti-inflammatory effects of camel milk.
| Agent | Effects | Model of study | Doses | Ref. |
|---|---|---|---|---|
| CM | Inhibited the volume of edema | Rats, paw edema | 33 ml/kg | ( |
| CM | Reduced the index of osteoarthritis, paw edema and gait score, increased IL-10 serum | Rats, RA | 10 ml/kg orally, 3 weeks | ( |
| CM | Decreased inflammatory angiogenesis, the collagen deposition and VEGF levels | Albino Swiss mice | 25-100 mg/kg/day, 14 days | ( |
| CM | Reduced TGF-β1 | Rats, T2D | 35 ml/rat/day | ( |
| Total lipid and fatty acids | Decreased IL-1β/18, regulated the expression of p50/p65 NF-κB subunits | – | ( | |
| C whey protein | Reduced apoptosis, T and B cells distribution (spleen and thymus), increased AKT and IκB-α phosphorylation | T1D, Mice | 100 mg/kg at 250 μl/day, 1 month | ( |
| Un-denatured whey proteins | Decreased IFN-γ and increased IL-2 | T1D rats | 100 mg/kg/day, 5 weeks | ( |
| C whey protein | Reduced IL-6, IL8, bloody stools, diarrhea, weight, and large intestine inflammation | Balb/c mice with colon cancer | – | ( |
| CM | Improved leukocyte infestation, pathological changes, MPO and caspases-3 activities | Rats with TNBS-induced colitis | 10 ml/kg | ( |
| CM | Decreased CD8+ T cells, increased CD4+ T and CD44+ CD4+ cells | Mice model of ACC | 2 g/kg/day in 200 µL | ( |
| CM | Reduced ulcers number, ulcers length, ulcer index and the volume of gastric juice | Rats, gastric ulcers | 5 ml/kg | ( |
| CM | Reduced IL-1β, increased IL-10 | C57BL/6J mice | 0.4 ml/day, 14 days, | ( |
| Fermented CM | Reduced CRP and IL-1ß | HFD-induced … in rats | – | ( |
| CM | Reduced IL-6 expression | Liver injury, rats | 100 ml/day | ( |
| Lactic acid bacteria | Decreased in IL-6 | Acute liver damage, mice | for 7 weeks | ( |
| CM | Increased IL-10, DOPA and AChE, improved sensorimotor function and impaired memory | FNP-induced neurotoxicity in rats | 2 ml/rat/day | ( |
| CM | Reduced IL-1β in lung tissue and neutrophil infiltration | Rats, ARDS | 10 mL/kg | ( |
| CM | Inhibited MPO, IL-1β, IL-18 and MCP-1 | A model of renal toxicity in rats | 10 ml/kg p.o. | ( |
| CM | Decreased renal inflammation | Cyclosporine-induced RI in rats | 10 ml/kg, 3 weeks | ( |
| CM | Inhibited single-cell chemotactic protein, hyaluronic acid and TGF-b1 serum levels | Hepatitis C infected patients | 5 L/week, 2 month | ( |
| CM | Decreased IL-4, increased IFN-γ | Chronic hepatitis Patients | – | ( |
| CM | Decreased serum TARC | Double-blind in autism patients | 500 ml/day | ( |
ACC, Acute and chronic colitis; AChE, Acetylcholinesterase; AKT, Protein kinase B; ARDS, Acute respiratory distress syndrome; CM, Camel milk; CRP, C reactive protein; DOPA, Dopamine; FNP, Fenpropathrin; IFN-γ, Interferon gamma; IκB-α, Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-alpha; IL, Interlukin; MCP-1, Monocyte chemoattractant protein-1; MPO, Myeloperoxidase; NF-κB, Nuclear factor-kappa B; RA, Rheumatoid arthritis; TARC, Thymus and activation‐regulated chemokine; TGF-β1, Transforming growth factor-beta1; TNBS, Trinitrobenzene sulfonic acid; T1D, Type 1 diabetes; T2D, Type 2 diabetes; VEGF, Vascular endothelial growth factor; HFD, High-fat diet; RI, Renal injury.
Antioxidant effects of Camel milk.
| Agent | Effects | Model of study | Doses | Reference |
|---|---|---|---|---|
| CM | Increased ACE inhibitor activity | TEAC | – | ( |
| CM casein | Inhibited ABTS, DPPH and FRAP activities | ABTS, DPPH and FRAP method | – | ( |
| CM non-fat powder | Increased the antioxidant activity | ABTS, DPPH and FRAP method | – | ( |
| CM | Increased SOD and CAT in liver homogenates | CYP-induced leukopenia in mice | 2 ml/day for 10 days | ( |
| CM | Reduced lipid peroxide and NO, increased GSH and TAC in serum | RA model of rat | 10 ml/kg, 3 weeks | ( |
| Fermented CM | Improved the activities of SOD, CAT, GPx | Mice heart tissue exposed to CCl4 | 100 mg/kg | ( |
| CM and its exosomes | Reduced MDA and iNOS, increased SOD, CAT and GPx activities | Rats and MCF7 breast cancer cells | 1 ml/rat, orally | ( |
| CM protein hydrolysates | Reduced MDA and GSH, improved SOD activity | Diabetic rats | 100,-1000 mg/kg, 8 weeks | ( |
| CM peptide | Increased SOD, CAT and GSH, decreased MDA | Diabetic rats | 25 mg/kg, 7 days | ( |
| CM | Reduced MDA, increased SOD and CAT | Rabbits model of diabetes | 7 ml/kg, 4 weeks | ( |
| CM | Decreased MDA, increased CAT, GR and SOD | Rat model of diabetes | – | ( |
| CM | Increased SOD, CAT and GSH | STZ -induced DM in rats | 50 ml/day, 8 weeks | ( |
| CM protein | Decreased ROS and ATF-3 expression | Mice model of TID | 100 mg/kg at 250 μl/day, 1 month | ( |
| CM | Reduced MDA, increased GST and SOD | Rats model of liver disease | 100 ml/day | ( |
| CM | Inhibited MDA and MPO, restructured SOD and GST activities | GM-induced liver damage in rats | 5 mL/rat/day | ( |
| Fermented CM | Increased SOD, GPx, CAT and GSH in the liver, decreased MDA | CCl4 liver damage in mice | – | ( |
| CM | Reduced hepatic MDA and increased TAC | Alcohol-induced hepatotoxicity, rats | 2 ml/day | ( |
| CM | Increased GSH and CAT, decreased MDA | Rats with NAFLD | 50 ml/day, for 8 weeks | ( |
| C Lactoferrin | Decreased NO | HCT-116 colon cancer cells | – | ( |
| CM | Reduced lipid peroxides and NO | Rats model of IBD | 20 ml/kg/day gavage | ( |
| CM | Increased SOD and GSH, decreased MDA | C57BL/6J mice | 0.4 ml/day, 14 days | ( |
| CM | Reduced NO, MDA, MPO and caspase-3 | FNP-induced neurotoxicity in rats | 2ml/day | ( |
| CM | Reduced MDA, MPO and TAC in lung tissue | Rats model of ARDS | 10 mL/kg/day | ( |
| CM | Suppressed oxidative stress, improved GSH, SOD, GPx and TAC | 5-FU-induced renal toxicity in rats | 10 ml/kg p.o. | ( |
| CM | Reduced MPO activity | Cyclosporine-induced kidney damage in rats | 10 ml/kg/day, 3 weeks, gavage | ( |
| CM | Increased SOD and CAT activities | CdCl2-induced toxicity in rats | 2 ml, 21 days | ( |
| CM | Increased SOD, CAT and GSH activities | CdCl2-induced HMiA in rats | – | ( |
| CM | Reduced TBARS and HP, increased GSH, SOD and CAT activities | AlCl3-induced oxidative stress rat | 1 ml, 30 days | ( |
| CM | Increased in plasma levels of GSH, SOD, decreased MPO | Double-blind RCT in ASD patients | 500 ml/day, 2 weeks | ( |
ABTS, 3-ethylbenzthiazoline-6-sulphonic acid; AlCl3, Aluminum chloride; ARDS, Acute respiratory distress syndrome; ASD, Autism spectrum disorder; CM, Camel milk; CCl4, Carbon tetrachloride; CYP, Cyclophosphamide; DN, Diabetic nephropathy; DPPH, 2,2-diphenyl-1-picryl-hydrazyl-hydrate; FRAP, Ferric reducing antioxidant power; GM, Gentamicin; GPx, Glutathione peroxidase; GR, Glutathione reductase; GSH, Glutathione; GST, Glutathione transferase; HP, Hydroperoxide; IBD, Inflammatory bowel disease; iNOS, Inducible nitric oxide synthase; MDA, Malondialdehyde; MPO, Myeloperoxidase; NAFLD, Nonalcoholic fatty liver disease; NO, Nitric oxide; NOX-1, Nicotinamide adenine dinucleotide phosphate oxidase; RA, Rheumatoid arthritis; SOD, Superoxide dismutase; TAC, Total antioxidant capacity; TNBS, Trinitrobenzene sulfonic acid; CdCl2, Cadmium Chloride; HMA, Hypocromic microcytic anemia; TEAC, Trolox equivalent antioxidant capacity.
Immunomodulatory effects of camel milk.
| Agent | Effects | Model of study | Doses | Reference |
|---|---|---|---|---|
| CM | Reduced TNF-α | Male offspring of pregnant female rat model induced by VPA | 2 ml/p.o | ( |
| CM | Reduced TNF-α in serum | Rats, adjuvant-induced arthritis | 10 ml/kg, 3 weeks | ( |
| CM | Reduced TNF-α | Alcohol-induced hepatotoxicity in male rats | 2 ml | ( |
| CM | Reduced TNF-α and TGF-β | Angiogenesis model in mice | 25-100 mg/kg/day, 14 days | ( |
| CM | Reduced TNF-α | Rat model of T2D | 35 ml/day | ( |
| Total lipid and fatty acids | Decreased TNF-α | – | ( | |
| C whey protein | Decreased IL-1β, IL-6, increased IL-4 | Mice model of T1D | 100 mg/kg B.W at 250 μl/d, 1 month | ( |
| Un-denatured whey proteins | Increased B cells, mitogen-stimulated lymphocyte proliferation, reduced T cells and TNF-α | Mice model of T1D, | 100 mg/kg in 250 μl/day, 5 weeks | ( |
| Fermented CM | Reduced TNF-α | High-fat diet in twenty-eight albino rats | 1 ml | ( |
| Lactic acid bacteria | Reduced TNF-α | LPS/D-GalN in mice | – | ( |
| CM | Reduced TNF-α in the colon | TNBS-induced colitis in rats | 10 ml/kg, gavage | ( |
| CM | Reduced TNF-a | ACC-induced DSS in mice | – | ( |
| CM whey | Reduced IFN-γ and IL8 in colon tissue | Balb/c CRC mice | – | ( |
| CM | Reduced TNF-α | Radiation-induced intestinal damage in mice | 0.2 ml, 14 days | ( |
| CM | Reduced TNF-α | FNP in rats | 2ml/day | ( |
| CM | Reduced TNF-α | ARDS rats | 10 ml/kg | ( |
| CM | Inhibited TNF-α | Renal toxicity in rats | – | ( |
| CM | Reduced TNF-α, MCP-1, IL-1β and IL-18 | Cyclosporine-induced kidney damage, rats | 10 ml/kg/day, 3 weeks | ( |
| CM | Reduced TNF-a | Clinical study, 25 patients | 5 L/week, 2 months | ( |
ACC, Acute and chronic colitis; CM, Camel milk; DSS, Sodium dextran sulfate; IFN-γ, Interferon gamma; IL, Interleukin; MCP-1, Monocyte chemoattractant protein-1; T1D, Type 1 diabetes; T2D, Type 2 diabetes; TGF-β1, Transforming growth factor-beta1; TNF-α, Tumor Necrosis Factor-alpha; VPA, Valproic acid.
Effects of bioactive peptide of camel milk.
| Agent | Effects | Model of study | Reference |
|---|---|---|---|
| LEEQQQTEDEQQDQL, YLEELHRLNAGY and RGLHPVPQ | Inhibited free radicals, Increased SOD and CAT | HepG2 cells | ( |
| P-CCP and P-CWP | Increased the tolerance of yeast cells to peroxide oxidative stress | ( | |
| Bioactive components of CM and colostrum proteins | Increased antioxidant activity and ACE inhibitors | ( | |
| CMPH | Increased the radical inhibition of DPPH and its antioxidant properties | ( | |
| Colostrum and CM | Stimulated specific immune responses | Rats infected with Schistosoma mansoni | ( |
| CM | Reduced serum enzymes, integrity of the liver cell membrane | Paracetamol-induced toxicity | ( |
| Camel whole casein and β-CN | Increased the antioxidant and ACE inhibitor activity | ( | |
| WP | Increased antioxidant activity | ( |
ACE, Angiotensin I-converting enzyme; β-CN, Beta-casein; CAT, Catalase; CM, Camel milk; CMPH, CM protein hydrolysis; SOD, Superoxide dismutase; WP, Whey protein.
Figure 2Various mechanisms of anti-inflammatory, antioxidant and immunomodulatory effects of Camel milk.
| ABTS | 3-ethylbenzthiazoline-6-sulphonic acid |
| ACE | Angiotensin-converting enzyme |
| AChE | Acetylcholinesterase |
| ACP | Acid phosphatase |
| AKT | Protein kinase B |
| ALP | Alkaline phosphatase |
| ALT | Alanine aminotransferase |
| ARDS | Acute respiratory distress syndrome |
| α-La | Alpha-lactalbumin |
| ASD | Autism spectrum disorder |
| AST | Aspartate aminotransferase |
| β-CN | Beta-Caseins |
| β-Lg | Beta-lactoglobulin |
| BUN | Blood urea nitrogen |
| CAT | catalase |
| CLA | Conjugated linoleic acid |
| CM | camel milk |
| CMPH | Camel milk protein hydrolysis |
| CRC | Colorectal Cancer |
| CRP | C reactive protein |
| CWP | Camel whey protein |
| CYP | Cyclophosphamide |
| DAI | Disease activity index |
| DMWP | Un-denatured whey proteins |
| DN | Diabetic nephropathy |
| DNA | Deoxyribonucleic acid |
| DOPA | Dopamine |
| DPPH | 2;2-diphenyl-1-picryl-hydrazyl-hydrate |
| DSS | Sodium dextran sulfate |
| ERK | Extracellular signal-regulated kinases |
| Fas | Programmed cell death-receptor |
| FCM | Fermented camel milk |
| FNP | Fenpropathrin |
| FRAP | Ferric reducing antioxidant power |
| GPx | Glutathione peroxidase |
| GR | Glutathione reductase |
| GSH | Glutathione |
| GST | Glutathione transferase |
| γ-GT | gamma glutamyl transferase |
| HDL | high-density lipoprotein |
| HP | Hydroperoxide |
| IBD | Inflammatory bowel disease |
| IFN-γ | Interferon gamma |
| Ig | Immunoglobulin |
| IκB-α | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
| IL | Interleukin |
| iNOS | Inducible nitric oxide synthase |
| JNK | c-Jun N-terminal kinases |
| KIM-1 | Kidney Injury Molecule-1 |
| LAB | Lactic acid bacteria |
| LDH | Lactate dehydrogenase |
| Lf | Lactoferrin |
| LPS | Lipopolysaccharide |
| MAPK | Mitogen-activated protein kinases |
| MCP-1 | Monocyte chemoattractant protein-1 |
| MDA | malondialdehyde |
| MPO | Myeloperoxidase |
| NAFLD | Nonalcoholic fatty liver disease |
| NF-κB | Nuclear factor kappa B |
| NO | Nitric oxide |
| NOX-1 | Nicotinamide adenine dinucleotide phosphate oxidase |
| PALS | Periarteriolar lymphoid sheaths |
| PGRP-1 | Peptidoglycan recognition protein-1 |
| RA | Rheumatoid arthritis |
| RIS | Radiation injury score |
| ROS | Reactive oxygen species |
| SOD | Superoxide dismutase |
| TAC | Total antioxidant capacity |
| T1D | Type 1 diabetes |
| T2D | Type 2 diabetes |
| TFA | Total fatty acids |
| TGF-β1 | Transforming growth factor beta 1 |
| Th | T helper |
| TL | Total lipids |
| TLR | Toll-like receptor-4 |
| TNBS | Trinitrobenzene sulfonic acid |
| TNF-α | tumor Necrosis Factor alpha |
| VEGF | vascular endothelial growth factor |
| VPA | Valproic acid |